|
| 1 |
|
Conditions listed in this trial |
|
|
Osteoporosis |
|
| 2 |
|
More general conditions related to this trial |
|
|
Bone Diseases |
|
|
Bone Diseases, Metabolic |
|
|
Musculoskeletal Diseases |
|
| 3 |
|
Interventions listed in this trial |
|
|
conjugated estrogens |
|
|
Medroxyprogesterone |
|
| 4 |
|
Additional drug interventions recognized in this trial |
|
|
Estrogens, Conjugated (USP) |
|
|
Medroxyprogesterone 17-Acetate |
|
| 5 |
|
More general drug interventions related to this trial |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Hormonal |
|
|
Contraceptive Agents |
|
|
Contraceptive Agents, Female |
|
|
Contraceptive Agents, Male |
|
|
Contraceptives, Oral |
|
|
Contraceptives, Oral, Synthetic |
|
|
Estrogens |
|
|
Hormones |
|
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Reproductive Control Agents |
|
|
Therapeutic Uses |
|
| 6 |
|
Sponsors listed in this trial |
|
|
National Institute of Dental and Craniofacial Research (NIDCR) |
|
|
Washington University School of Medicine |
